A double‑blind randomized trial tested a hydrogel embedded with placental mesenchymal stem cells (PMSCs) for treating radiation-induced skin injury. The trial reported accelerated wound healing and improved dermatologic outcomes versus control, suggesting a regenerative approach to a common complication of radiotherapy. Investigators underscored endpoints including time to epithelialization, pain scores, and histologic markers of repair. While safety data were favorable, authors called for larger multicenter trials to confirm efficacy, define optimal dosing, and evaluate long-term outcomes prior to widespread clinical adoption.